O Shaughnessy Asset Management LLC Raises Holdings in argenx SE (NASDAQ:ARGX)

O Shaughnessy Asset Management LLC raised its stake in argenx SE (NASDAQ:ARGX) by 44.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,138 shares of the company’s stock after purchasing an additional 969 shares during the period. O Shaughnessy Asset Management LLC’s holdings in argenx were worth $1,930,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in ARGX. Whipplewood Advisors LLC acquired a new stake in argenx in the fourth quarter valued at approximately $37,000. Global Retirement Partners LLC raised its holdings in shares of argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after purchasing an additional 48 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after purchasing an additional 61 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in shares of argenx by 78.6% during the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock worth $46,000 after purchasing an additional 33 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its stake in shares of argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock worth $47,000 after purchasing an additional 21 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Stock Performance

Shares of ARGX opened at $555.11 on Friday. The stock has a market capitalization of $33.73 billion, a P/E ratio of -630.81 and a beta of 0.60. argenx SE has a 1 year low of $352.77 and a 1 year high of $678.21. The company’s fifty day moving average is $621.43 and its two-hundred day moving average is $602.61.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Sell-side analysts predict that argenx SE will post 3.13 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on ARGX shares. Sanford C. Bernstein raised argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. Wells Fargo & Company upped their price target on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Piper Sandler boosted their price objective on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. William Blair restated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Finally, Truist Financial reiterated a “buy” rating and set a $700.00 price target (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.